The right dose at the right time is critical for any patient living with a disease. Precision dosing has become a widely discussed topic, and a growing literature recognizes the implications of imprecise dosing on public health, related to both cost and adverse outcomes. 

For patients living with inflammatory diseases, many physicians have shared their data and expressed concerns about knowing the infliximab trough level they wanted to achieve but not fully understanding the relationship between dose and subsequent trough, which is needed to achieve the desired trough level from a specific dose. In response to this medical need, Baysient has developed two different software applications that allow these physicians and others to individualize dosing to achieve a specific physician selected trough level.

Pharmacometric Analysis of Individual Patient Data

Built to provide individualized treatments for patients with improved outcomes, Baysient develops SaaS, cloud-based software that provides medical providers with a full line of individual dosage-determination products. Working with gastroenterologists to safely reduce the incidence of anti-drug antibodies during maintenance, Baysient’s revolutionary softwares, iDose and T3, enable individualized and improved treatment outcomes for inflammatory diseases.


Baysient’s first patented web-based application, iDose, creates an individual patient pharmacometric model from the respective patient’s clinical characteristics, previous infliximab dosing history, drug concentrations, and other specific lab results. This model estimates the rate at which the patient’s body will clear infliximab from their system. The software is capable of calculating a variety of precise, model-informed dosing regimens. Each combination of dose amount and respective dosing interval will achieve the physician selected trough concentration for the individual patient.

The iDose software may be used for both infliximab induction and maintenance. iDose is best for early treatment because patients’ clearances are often changing very quickly during induction. iDose can be used without a measured infliximab concentration.


Baysient recently launched a new app, Time To Target. T3 is an algorithm that determines the effective half-life of infliximab for patients in maintenance based on a measured drug concentration, patient weight, and previous dose. Identifying the half-life value provides physicians with an estimate of the length of time until the drug concentration will fall below the target level. T3 regulates the respective durations to reach the target concentration for dose amounts of 5, 7.5, 10, or 15 mg/kg of infliximab when administered intravenously. A new module for the upcoming subcutaneous formulation of infliximab has been developed and is in testing.

Using T3 in maintenance allows the physician and patient to select a dosing interval that ensures the infliximab concentration level will be high enough for an adequate period of time to effectively treat the patient’s condition. T3 requires a measured concentration.

Importance of Routine Blood Draws Covered by Insurance

Routine blood draws are critical as they help physicians know how long infliximab is present in the patient’s body before they clear the drug. By monitoring clearance and half-life values, physicians will be able to provide an accurate dosing interval, allowing the drug to be present long enough and at a high enough exposure to treat the patient’s condition while at the same time reducing the initially high concentrations seen with administration of a high dose of infliximab. 

When a drug enters the body, it is absorbed into the blood or administered as an IV directly into the blood and distributed throughout the body. Once the drug reaches a peak level, the drug levels will begin to fall steadily as it’s eliminated from the body. Without routine blood draws, physicians will not have an accurate indication of how fast (or slowly) the drug is cleared from the patient, causing the patient to lose response to the drug, or if the drug clears slowly, potentially causing adverse events. 

Better Outcomes at a Lower Cost

Precision drug dosing ensures that patients get the exact right dose, which improves their clinical outcomes, reduces adverse drug events, and decreases overall healthcare costs both for the individual and the healthcare industry. 

If drug regimens are effectively tailored to each individual, healthcare costs will decrease because there will be an optimized use of limited healthcare resources. You can learn more about how precision dosing lowers overall healthcare costs in our blog.

See How Baysient Can Help!

We value the fact that all patients are unique and deserve individual treatments tailored specifically for them, changing as they heal. There is no single dose that is right for all patients. That is why our goal is to provide individualized treatments for patients with improved outcomes at lower costs.

Schedule a demo today to see how Baysient’s cloud-based softwares can help your practice.